ABSTRACT
. It has been reported that cancer specific mortality 3 or all cause mortality 4 was lower for patients with cancer diagnosed during the summer or the fall, the seasons with the highest blood levels of 25-hydroxyvitamin D, than for those diagnosed in the winter.
The prognostic significance of circulating 25-hydroxyvitamin D levels among cancer patients has been examined in a limited number of studies [5] [6] [7] [8] [9] [10] [11] . Higher 25-hydroxyvitamin D levels were associated with better overall survival in patients with non-small-cell lung cancer with stage IB-IIB but not in those with stage IA, III or IV [5] [6] . In the Nurses' Health Study and the Health Professionals Follow-up Study, 304 participants were diagnosed with colorectal cancer 7 . Higher pre-diagnosis 25-hydroxyvitamin D levels were associated with a significant reduction in overall mortality but not with cancer specific mortality. For breast cancer, lower pre-diagnosis plasma vitamin D levels were associated with a higher risk of distant recurrence and of death in one study 8 while no association was observed with recurrence-free survival in another prospective cohort 9 . In another study, serum 25-hydroxyvitamin D levels were measured in 160 patients with prostate cancer 10 . The men with 25-hydroxyvitamin D serum levels below 50 nmol/L had increased risks of cancer 5, 12 .
No association was observed between vitamin D intake and overall survival or disease-free survival in 321 patients with early-stage non-small cell lung cancer. However, among the 151 patients who had surgery in the summer, those with higher vitamin D intake had significantly better outcomes 12 .
In the present study, we prospectively examined the relationship of dietary intake and serum level of vitamin D with disease outcomes in a large cohort of patients with localized (stage I and II) head and neck cancer.
PATIENTS AND METHODS

Study population
Between October 1, 1994, and June 6, 2000, 540 patients with stage I or II head and neck cancer (HNC) were recruited in five radiation therapy centers in the province of Quebec, Canada to participate in a randomized controlled trial 13 . The institutional review 6 board of each participating center approved the study protocol. All patients gave written informed consent prior to randomization. Patients with an average over the preceding year daily supplement intake of beta carotene or vitamin E above 6.0 mg and 50 IU, respectively were not eligible for the trial. Patients were randomly assigned to receive a daily supplementation consisting of vitamin E (one capsule of 400 IU dl-α-tocopherol) and β-carotene (one capsule of 30 mg) or placebos during radiation therapy and for 3 years after radiation therapy ended. Concerns about adverse effects of β-carotene supplementation prompted the investigators to halt the use of β-carotene after the first 156 patients had been enrolled. The trial was continued with alpha-tocopherol alone.
The main results of the trial were an increased incidence of second primary cancers (SPC) during the period of supplementation 13 and a decreased overall survival 14 All death certificates were obtained from the Institut de la statistique du Québec. Three main separate outcomes were studied: cancer recurrence, SPC incidence, and overall mortality.
Statistical analyses
We International Journal of Cancer (i.e. supplements or placebos). The proportionality assumption of the regression models was formally tested using the standardized score process. The overall adequacy of the models was assessed by examining deviance residuals 19 . All statistical tests were twosided. The analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC).
RESULTS
The baseline personal, clinical, dietary and serologic characteristics of study participants are presented in Table 1 
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DISCUSSION
In this large mature cohort of patients treated for localized HNC, we observed no association between pre-treatment dietary or serum vitamin D measures and disease outcomes. Although this could be viewed as a negative result, our study remains informative as it is in the top of studies of the prognostic significance of vitamin D in cancer patients in terms of number of patients, duration of follow-up, and number of death events [5] [6] [7] [8] [9] [10] [11] [12] . Furthermore, few investigators have collected dietary information among cancer patients before initial therapy, in addition to serum samples.
In the planning of our randomized trial, which evaluated the effects of a supplementation with alpha-tocopherol and beta-carotene, we purposely developed a semi-quantitative food frequency questionnaire to assess in patients with HNC the intake over the previous year of the main energy providing nutrients and micronutrients such as vitamin A, vitamin E, and carotenoids. In this validation study, the correlations between dietary intakes and circulating levels were respectively 0.29 (p=0.02) for betacarotene and 0.39 (p=0.005) for alpha-tocopherol 
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The 25-hydroxyvitamin D circulating levels in our study population ranged from 19
to 135 nmol/L with a mean of 64 nmol/L. These levels are comparable to those reported in breast cancer patients in the Toronto area 8 and in patients with colorectal cancer in the United-States
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. In the Boston area, patients with lung cancer had markedly lower levels of 25-hydroxyvitamin D 5, 6 . The interquartile range in our study (48 to 78 nmol/L) is wider than those observed in most previous studies. There is presently no consensus on adequate or optimal levels of vitamin D measured as serum 25-hydroxyvitamin D levels, and these depend on the health outcome considered [22] [23] .
Our results do not support the hypothesis of an association between diet or serum vitamin D and cancer recurrence or mortality in patients with head and neck cancer. Although there was some indication of a lower mortality for patients with higher serum vitamin D levels in the crude analysis, this trend was much weaker after controlling for multiple confounders. There is, to our knowledge, no other published report investigating the relation of vitamin D to recurrence or survival among HNC patients.
A critical second look at the published studies of the prognostic significance of vitamin D in cancer patients suggests that the association varies according to cancer site. There is a clear and significant downward trend of overall mortality in patients with colorectal cancer 7 . In patients with melanoma, serum hydroxyvitamin D levels were significantly associated with recurrence free survival but not with overall survival 11 . For breast cancer, two large prospective studies yielded opposite results 8, 9 . No significant association with overall survival was observed overall in cohorts of patients treated for 5, 6, 12 . Thus, the current evidence in favor of a beneficial effect of vitamin D on cancer outcomes remains weak.
In our study, patients with serum 25-hydroxyvitamin D level in the uppermost quartile had almost half the rates of lung cancer incidence and mortality than those in the lowest quartile. HNC patients are at very high risk of new lung cancer presumably because of field cancerization and common smoking exposure. Two prospective studies have examined the relationships between pre-diagnosis 25-hydroxyvitamin D circulating levels and lung cancer risk 24, 25 . Among the participants in the Third National
Health and Nutrition Examination Survey, there was no association between serum 25-hydroxyvitamin D level and mortality from lung cancer 24 . In a large cohort study in Finland, baseline serum 25-hydroxyvitamin D level was inversely related to lung cancer risk but the overall association was no longer significant in a multivariate model 25 . In this latter study, age and sex were effect modifiers and significant associations were observed in younger participants and in women. It is possible that a true association exists between vitamin D and lung cancer risk, but the studies that have examined this hypothesis, including ours, did not have sufficient power.
In conclusion, our study results do not provide support to the hypothesis that pretreatment vitamin D status is related to disease outcomes among patients with localized head and neck cancer. Further investigations of the relationships between vitamin D
and cancer incidence or outcome should take into account genetic variants of key genes involved in vitamin D metabolism. 
